🔔Stock Alerts via Telegram — Free for All Users

ISRG Stock Risk & Deep Value Analysis

Intuitive Surgical Inc

Healthcare • Medical Instruments & Supplies

DVR Score

3.0

out of 10

Risk Trap

What You Need to Know About ISRG Stock

We analyzed Intuitive Surgical Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran ISRG through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.

Updated Apr 20, 2026Run Fresh Analysis →

ISRG Risk Analysis & Red Flags

What Could Go Wrong

While highly unlikely, a disruptive competitor could emerge with a significantly cheaper, equally effective, or technologically superior robotic platform that rapidly gains market share, eroding ISRG's formidable installed base and recurring revenue streams. Combined with ongoing regulatory challenges or unresolved product safety issues, this could significantly impact profitability and market dominance.

Risk Matrix

Overall

Moderate

Financial

Low

Market

Medium

Competitive

Medium

Execution

Medium

Regulatory

Medium

Red Flags

  • Net insider selling of 32,943 shares for ~$17.28M in the last quarter (Q1 2026 period).

  • Recent FDA recall of da Vinci Xi EndoWrist Suction Irrigator and embedded software.

  • Reports of safety & cybersecurity issues (stapler/reload products, administrative-network data breach).

  • 2026 procedure growth guidance (13%-15%) is lower than 2025 (18%).

  • Estimated 1.2% of revenue impact from tariff headwinds.

Upcoming Risk Events

  • 📅

    Q1 2026 earnings miss or weak forward guidance

  • 📅

    Increased competitive pressure from new market entrants or established medical device giants

  • 📅

    Further regulatory scrutiny or product safety issues (e.g., additional recalls)

  • 📅

    Escalation of tariff impacts on gross margins

When to Reconsider

  • 🚪

    Sustained quarter-over-quarter decline in core procedure growth rates below low double-digits.

  • 🚪

    Major market share loss to a direct competitor, as indicated by system placements or recurring instrument sales.

  • 🚪

    Multiple severe product recalls or significant, unresolved regulatory fines/sanctions.

  • 🚪

    Gross margin consistently falling below the 65% level due to competitive pricing or cost pressures.

Unlock ISRG Risk Analysis & Red Flags

Create a free account to see the full analysis

What Does Intuitive Surgical Inc (ISRG) Do?

Market Cap

$166.65B

Sector

Healthcare

Industry

Medical Instruments & Supplies

Employees

15,638

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.

Visit Intuitive Surgical Inc Website

Investment Thesis

Intuitive Surgical is a high-quality, market-leading innovator in robotic-assisted surgery, poised for sustained double-digit growth driven by increasing procedure adoption, global expansion, and new platform (da Vinci 5, Ion) penetration. Its razor-and-blade business model ensures highly profitable, recurring revenue, supported by a wide economic moat, making it a strong long-term compounder within the healthcare sector.

Is ISRG Stock Undervalued?

Intuitive Surgical (ISRG) continues to demonstrate strong operational performance, evidenced by its Q4 2025 revenue growth of 18.8% YoY and robust EPS beat. It maintains its undisputed leadership in robotic-assisted surgery, supported by a growing installed base of 11,423 da Vinci systems and impressive Ion system adoption. The company's formidable moat, built on IP, high switching costs, and extensive R&D, ensures durable future growth within its expanding market. However, the premise of achieving a 10x return ($1.66 trillion valuation) within 3-5 years for a company of its current $166.65 billion market cap remains extraordinarily improbable. While a premier long-term compounder, its established large-cap status fundamentally limits multi-bagger potential within the aggressive timeframe, a view consistent with previous assessments. Recent product recalls, cybersecurity reports, and tariff headwinds introduce minor operational risks, partially offset by solid financial execution, thus maintaining the low 10x potential score.

Unlock the full AI analysis for ISRG

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

ISRG Price Targets & Strategy

12-Month Target

$598.36

Bull Case

$750.00

Bear Case

$450.00

Valuation Basis

Based on 65x forward P/E applied to estimated FY26 EPS of $9.20 ($598.36 / 65).

Entry Strategy

Consider dollar-cost averaging on dips towards the $450-$470 range, potentially near the 200-day moving average (SMAs not provided in research, so using recent support).

Exit Strategy

Target profit-taking at $598-$620, reassess at $750. Implement a stop-loss order if the stock breaks below $420, signaling a potential shift in sentiment or fundamentals.

Portfolio Allocation

3-5% for moderate risk tolerance, reflecting strong company fundamentals but limited multi-bagger potential.

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is ISRG Financially Healthy?

Valuation

P/E Ratio

58.35

Forward P/E

45.80

PEG Ratio

3.58

Profitability

Gross Margin

66.00%

Operating Margin

29.27%

Net Margin

28.38%

Return on Equity

16.36%

Revenue Growth

20.51%

EPS

$7.88

Balance Sheet

Current Ratio

4.87

Quick Ratio

3.79

Cash Flow

Free Cash Flow

$1.96B

Other

Beta (Volatility)

1.56

Does ISRG Have a Competitive Moat?

Sign in to unlock

Moat Rating

🏰 Wide

Moat Trend

Stable

Moat Sources

3 Identified

Switching CostsIntangible Assets/IPEfficient Scale

ISRG's moat is highly durable due to the deep integration of its systems into surgical workflows, the substantial investment in training required for surgeons, and its extensive patent portfolio. Replacing or significantly competing with its installed base effectively requires monumental capital and time, making its leadership highly resilient.

Moat Erosion Risks

  • Disruptive technological innovation from a competitor that bypasses existing surgical techniques or intellectual property.
  • Significant and persistent safety issues or regulatory setbacks that erode surgeon trust and institutional adoption.
  • Aggressive pricing strategies from new entrants that significantly reduce the economic advantage of da Vinci systems.

ISRG Competitive Moat Analysis

Sign up to see competitive advantages

ISRG Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Neutral. While a well-respected company, recent product recalls and cybersecurity news may temper sentiment temporarily.

Institutional Sentiment

Positive. 83.64% institutional ownership and a 'Moderate Buy' analyst consensus with price targets up to $750, despite some trimming to $550.

Insider Activity (Form 4)

Net insider selling: VP Fredrik Widman and EVP Myriam Curet sold shares, contributing to a total of 32,943 shares sold for ~$17.28M over the last quarter.

Options Flow

Normal options activity. No significant unusual put/call ratio skew or large institutional block trades were flagged in the provided intelligence.

Earnings Intelligence

Next Earnings

2026-04-21 (after market close)

Surprise Probability

Medium

Historical Earnings Pattern

ISRG typically experiences significant stock movement (5-10% volatility) post-earnings, heavily influenced by procedure growth rates, system placements, and forward guidance, especially regarding new product adoption.

Key Metrics to Watch

Da Vinci procedure growth guidance for 2026Da Vinci system placements for Q1 2026Ion system placements and procedure growthGross margin impact from tariffs and supply chainUpdates on product recall and cybersecurity issues

Competitive Position

Top Competitor

MDT (Medtronic)

Market Share Trend

Stable. Intuitive Surgical maintains a dominant market share in robotic-assisted surgery, continuously expanding its installed base and procedure volumes, though facing increasing competition in specific segments.

Valuation vs Peers

ISRG generally trades at a premium to broader medical device peers like Medtronic or Johnson & Johnson, reflecting its market dominance, superior growth, and high profitability within a specialized, high-growth niche.

Competitive Advantages

  • Extensive installed base and surgeon training ecosystem creating significant switching costs.
  • Strong intellectual property portfolio and continuous R&D investment.
  • High gross margins from recurring instrument and service revenue.
  • Established brand recognition and trust within the surgical community.

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive ISRG Stock Higher?

Near-Term (0-6 months)

  • Q1 2026 Earnings report (expected April 21, 2026)
  • Resolution and clear communication regarding da Vinci Xi EndoWrist Suction Irrigator recall

Medium-Term (6-18 months)

  • Accelerated adoption of da Vinci 5 and Ion systems post-launch phase
  • Expansion into new surgical procedure indications and global markets, particularly in emerging economies

Long-Term (18+ months)

  • Continued R&D leading to next-gen robotic platforms or significant AI integration
  • Deepening of the 'razor-and-blade' model, enhancing recurring revenue streams

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for ISRG?

  • Acceleration in da Vinci system placements and procedure growth exceeding guidance.

  • Successful integration of new technologies (e.g., AI/ML) into surgical platforms.

  • Maintenance or expansion of gross and operating margins despite tariff headwinds.

Bull Case Analysis

See what could go right with Premium

Competing with ISRG

See how Intuitive Surgical Inc compares to related companies

CompanyMarket CapDVR ScoreP/ERevenueProfit MarginRev Growth

Intuitive Surgical Inc

ISRG

$166.6B3.058.4$10.1B28.4%20.5%

AbbVie Inc

ABBV

$403.8B0.1171.8Compare →

Johnson & Johnson

JNJ

1.0Compare →

Eli Lilly and Co

LLY

$965.0B0.552.6Compare →

Pfizer Inc

PFE

$150.6B0.219.4$62.6B12.4%-1.6%Compare →

UnitedHealth Group Inc

UNH

$276.2B0.322.9$113.7B2.7%1181.0%Compare →

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

How Intuitive Surgical Inc Makes Money

Intuitive Surgical generates revenue primarily by providing robotic-assisted surgical systems, most notably the da Vinci platform, to hospitals and surgical centers globally. Its business model resembles a 'razor-and-blade' approach: initial sales of the expensive da Vinci systems are followed by high-margin, recurring revenue from the disposable instruments and accessories used in each surgery, as well as ongoing service contracts and training. This creates a deeply embedded ecosystem where the initial capital outlay is continually monetized through subsequent procedure volumes.

Read Full Business Model Breakdown

FAQ

What is the DVR Score for Intuitive Surgical Inc (ISRG)?

As of April 20, 2026, Intuitive Surgical Inc has a DVR Score of 3.0 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Intuitive Surgical Inc?

Intuitive Surgical Inc's market capitalization is approximately $166.6B. The company operates in the Healthcare sector within the Medical Instruments & Supplies industry.

What ticker symbol does Intuitive Surgical Inc use?

ISRG is the ticker symbol for Intuitive Surgical Inc. The company trades on the NMS.

What is the risk level for ISRG stock?

Our analysis rates Intuitive Surgical Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of ISRG?

Intuitive Surgical Inc currently has a price-to-earnings (P/E) ratio of 58.4. This is above the market average, suggesting the stock may be priced for high growth expectations.

Is Intuitive Surgical Inc's revenue growing?

Intuitive Surgical Inc has reported revenue growth of 20.5%. The company is showing strong top-line momentum.

Is ISRG stock profitable?

Intuitive Surgical Inc has a profit margin of 28.4%. This indicates strong profitability.

How often is the ISRG DVR analysis updated?

Our AI-powered analysis of Intuitive Surgical Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 20, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ISRG (Intuitive Surgical Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.

Navigated to ISRG Stock Risk & Deep Value Analysis